Compare Pinterest Inc (PINS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pinterest Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Pinterest Inc trades at $21.58 (market cap $12.67B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Pinterest Inc is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Pinterest Inc for 85 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PINS | SYRE | |
|---|---|---|
Market Cap | $12.67B | $7.52B |
Volume | 12,391,118 | 1,441,031 |
Sector | Media | Health |
52-Week High | $35.24 | $108.92 |
52-Week Low | $15.42 | $22.18 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $12.59B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $21.76, up 1.56% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue has grown from $2.8B in 2022 to $4.2B in 2025, though net income margin is modest at 5.46%. The company continues to innovate with new ad products like Visual Search Ads, enhancing its advertising moat. Analyst consensus is bullish with a $27.93 price target, but high valuation ratios and insider selling present cautionary notes.
The outlook for PINS is positive given consistent revenue growth and strategic ad initiatives, offering potential upside to the consensus target. However, risks include elevated P/E of 65.79, competitive pressures in social media advertising, and negative net cash flow trends. Investors should weigh strong fundamentals against valuation concerns and market volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
